Trial Profile
A trial to evaluate and compare efficacy and survival outcomes of sunitinib and pazopanib as first-line treatment of patients with metastatic renal-cell carcinoma (mRCC)
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 11 Aug 2016
Price :
$35
*
At a glance
- Drugs Pazopanib (Primary) ; Sunitinib (Primary)
- Indications Renal cell carcinoma
- Focus Therapeutic Use
- 11 Aug 2016 New trial record